Acute coronary disease athero-inflammation: Therapeutic approach

Thrombosis Journal

Volumn 1, Issue , 2003, Pages

  Altman, Raul ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; FLURBIPROFEN; HEPARIN; INDOBUFEN; MELOXICAM; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; ROFECOXIB; THROMBOXANE A2; TICLOPIDINE;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CELL INFILTRATION; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; ENZYME INHIBITION; GRAFT OCCLUSION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIVER METABOLISM; NONHUMAN; OBESITY; REVIEW; RHEUMATOID ARTHRITIS; SMOKING HABIT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSTABLE ANGINA PECTORIS; VASCULITIS;

EID: 4344683385     PISSN: 14779560     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-9560-1-2     Document Type: Review

References (53)

1. Corti R, Farkouh ME and Badimon JJ: The vulnerable plaque and acute coronary syndromes Am J Med 2002, 113:668-680.
2. Kereiakes DJ: The fire that burns within. C-reactive protein Circulation 2003, 107:373-374.
3. Altman R and Scazziota A: Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. Unexpected results after aspirin intake Thrombos Res 1986, 43:113-120.
4. Cyrus T, Sung S, Zhao L, Funk CD, Tang S and Praticò D: Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice Circulation 2002, 106:1282-1287.
5. Redondo S, Santos-Gallego CG and Ganado P et al.: Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β Circulation 2003, 107:626-629.
6. Altman R, Scazziota A, Rouvier J and Gonzalez C: Effect of sodium arachidonate on thrombin generation through platelet activation. -Inhibitory effect of aspirin Thrombos Haemostas 2000, 54:1109-1112.
7. Kharbanda RK, Walton B and Allen M et al.: Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin Circulation 2002, 105:2600-2604.
8. Airenne S, Surcel HM and Alakarppa H et al.: Chlamydia pneumoniae infection in human monocytes Infect Immun 1999, 67:1445-1449.
9. Godzik KL, O'Brien ER, Wang SK and Kuo CC: In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae J Clin Microbiol 1995, 33:2411-2414.
10. Tiran A, Gruber HJ, Graier WS, Wagner AH, van Leeuwen EBM and Tiran B: Aspirin Inhibits Chlamydia pneumoniae-induced nuclear factor-B activation, cytokine expression, and bacterial development in human endothelial cells Arterioscl Thromb Vasc Biol 2002, 22:1075-1080.
11. Blake GJ and Ridker PM: Novel Clinical Markers of Vascular Wall Inflammation Circ Res 2001, 89:763-771.
12. Bhatt DL and Topol EJ: Need to test the arterial inflammation hypothesis Circulation 2002, 106:136-140.
13. Topol EJ: Aspirin with bypass surgery - From taboo to new standard of care N Engl J Med 2002, 347:1359-1360.
14. Antithrombotic trialists' collaboration: Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infaraction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994, 308:81-106.
15. Antithrombotic trialists' collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002, 324:71-86.
16. Cleland JGF: Preventing atherosclerotic events with aspirin BMJ 2002, 321:103-105.
17. Baigent C, Collins R and Peto R: Article makes simple errors and could cause unnecessary deaths BMJ 2002, 324:167.
18. Sudlow C, Sandercock P and Warlow Ch: Antiplatelet therapy and atherosclerotic events BMJ 2002, 324:917.
19. Reilly M and FitzGerald GA: Gathering intelligence on antiplatelet drugs: the view from 30.000 feet. When combined with other information overviews lead to conviction BMJ 2002, 324:59-60.
20. Savi P, Pereillo JM and Uzabiaga MF et al.: Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 2000, 84:891-896.
21. Dunzendorfer S, Reinisch CM, Kaneider NC, Pechlaner Ch and Wiedermann ChJ: Inhibition of plasma-dependent monocyte chemokinesis and cytokine-triggered endothelial activation for neutrophil transmigration by administration of clopidogrel in man Acta Med Austriaca 2002, 29:100-106.
22. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E and Harder S: Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease Clin Pharmacol Ther 2003, 73:232-241.
23. Klinkhardt U, Graff J and Harder S: Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model Clin Pharmacol Ther 2002, 71:176-185.
24. Atalar E, Aytemir K and Haznedaroglu I et al.: Platelet and leukocyte deactivation after intracoronary stent placement in patients receiving combined antiplatelet therapy Clin Appl Thromb Hemost 2001, 7:116-121.
25. Wolf I, Mouallem M, Rath S and Farfel Z: Clopidogrel-induced systemic inflammatory response syndrome Mayo Clin Proc 2003, 78:618-620.
26. Brochier ML: Evaluation of flurbiprofen for prevention of rein-farction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial Eur Heart J 1993, 14:951-957.
27. Cataldo G, Heiman F, Lavezzari M and Marubini E: Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis Coron Artery Dis 1998, 9:217-222.
28. Sajadieh A, Wendelboe O, Hansen JF and Mortensen LS: Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial Am J Cardiol 1999, 83:1263-1265.
29. Ray WA, Stein CM, Hall K, Daugherty JR and Griffin MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study Lancet 2002, 359:118-123.
30. Rahme E, Pilote L and LeLorier J: Association between naproxen use and protection against acute myocardial infarction Arch Intern Med 2002, 162:1111-1115.
31. Vane JR, Bakhle YS and Botting RM: Cyclooxygenase 1 and 2 Ann Rev Pharmacol Toxicol 1998, 38:97-120.
32. Burleigh ME, Babaev VR and Oates JA et al.: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 2002, 105:1816-1823.
33. Bombardier C, Laine L and Reicin A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group N Engl J Med 2000, 343:1520-1528.
34. Catella-Lawson F, McAdam B and Morrison BW et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 1999, 289:735-741.
35. Catella-Lawson F and Crofford LJ: Cyclooxygenase inhibition and thrombogenicity Am J Med 2001, 110(Suppl 3A):28S-32S.
36. Chenevard R, Hülimann D and Béchir M et al.: Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 2003, 107:405-409.
37. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling Thromb Haemost 2001, 86:324-333.
38. Hong BK, Kwon HM, Lee BK, Kim D, Kim LJ and Kang SM et al.: Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions Yonsei Med J 2000, 4:82-88.
39. De Servi S, Mazzone A and Ricevuti G et al.: Granulocyte activation after coronary angioplasty in humans Circulation 1990, 82:140-146.
40. Pitt B, Pepine C and Willerson JT: Cycloogygenase-2 inhibition and cardiovascular events Circulation 2002, 106:167-169.
41. Crofford LJ, Oates JC and McCune WJ et al.: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 inhibitors: a report of four cases Arthritis Rheum 2000, 43:1891-1896.
42. Mukherjee D, Nissen SE and Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 2001, 286:954-959.
43. Hennan JK, Huang J and Barret TD et al.: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries Circulation 2001, 104:820-825.
44. Dalen J: Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction Arch Inter Med 2002, 162:1091-1092.
45. Konstam MA, Weir MR and Reicin A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib Circulation 2001, 104:2280-2288.
46. Mamdani M, Rochon P and Juurlink D et al.: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the eldery Arch Intern Med 2003, 163:481-486.
47. Azar RR, Rinfret S and Theroux P et al.: A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial) Eur Heart J 2000, 21:2026-2032.
48. Versaci F, Gaspardone A and Tomai F et al.: Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study) J Am Coll Cardiol 2002, 40:1935-1942.
49. Altman R, Luciardi HL and Muntaner J et al.: Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation. The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study Circulation 2002, 106:191-195.
50. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F and Maseri A: Widspread coronary inflammation in unstable angina N Engl J Med 2002, 347:5-12.
51. Rioufol G, Finet G and Andre-Fouet X et al.: Multiple atherosclerotic plaque rupture in acute coronary syndromes Circulation 2002, 106:657-671.
52. Schoenhagen P, Tuzcu M and Ellis SG: Plaque vulnerability, plaque rupture, and acute coronary syndromes. (Multi)-focal manifestation of a systemic disease process Circulation 2002, 106:760-762.
53. Keaney JF Jr and Vita JA: The value of inflammation for predicting unstable angina N Eng J Med 2002, 347:55-57.